Keyword: Sutent

Chi-Med's surufatinib, aiming to challenge Pfizer and Novartis, hits its goal in phase 3 neuroendocrine tumor trial in China.

Roche’s I-O rivals are hurtling toward a showdown in kidney cancer. But the Swiss drugmaker has decided to pull its horse out of the race.

Pfizer has long been kidney cancer player, but it’s looking to take things up a notch with its latest immunotherapy data.

Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.

Targeted by the Justice Department in an industrywide copay assistance investigation, Pfizer has now agreed to a $23.85 million deal with the feds.

Pfizer has been looking to expand Inlyta's use to kidney cancer patients at a high risk of disease recurrence after surgery—but it's fallen short.

With Tecentriq and Avastin's trial win over Sutent in first-line kidney cancer, Roche scored new points in its quest to advance the combo.

Pfizer’s old dog Sutent has shown it has one more trick to perform as a renal cancer treatment before being passed up by the new breed of I-O drugs.

Pfizer is counting on a new approval for Sutent, its kidney cancer drug, but an FDA advisory panel isn’t so sure.